Versha Banerji

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ...

Acalabrutinib met of zonder obinutuzumab versus chlorambucil-obinutuzumab bij onbehandelde CLL: ELEVATE-TN fase III